FAIL (the browser should render some flash content, not this).
FAIL (the browser should render some flash content, not this).

Development Stage Company

Tissue Genesis has a limited operating history, and has not yet commercialized any products and therefore, has not generated product revenues. To date, the company has focused on development of its BOS platform products and the development of autologous adipose-derived cells for use in various applications, including wound care solutions and endothelialized grafts for vascular applications. The company has been profitable in its early R & D stages due to government contract revenues. For the year ended December 31, 2004 and the four months ended April 30, 2005, Tissue Genesis’ preliminary net loss was approximately $1,092,024 and $314,558 respectively.




Capitalization

Please contact us for information regarding our capitalization.


Shareholder News:
  		• September 2007 Shareholder Newsletter
  		• September 2006 Shareholder Newsletter
  		• August 2005 Shareholder Newsletter

     

    For more information contact us at:

    Tissue Genesis, Inc.
    677 Ala Moana Boulevard
    Suite 1100
    Honolulu, HI 96813

    Phone: (808) 539-9331
    Fax: (808) 539-9345

    Email Tissue Genesis, Inc.
    www.tissuegenesis.com. © 2006
    Tissue Genesis Solutions | Informational Materials
    Home | Overview | Management | News & Events
    Investor Overview |     Contacts | Terms of Use| Privacy Policy